Holen Sie sich die Stockscreener-App
17.95
1.24%
0.22
Schlusskurs vom Vortag:
$17.73
Offen:
$17.92
24-Stunden-Volumen:
2.08M
Relative Volume:
1.84
Marktkapitalisierung:
$984.86M
Einnahmen:
$14.34M
Nettoeinkommen (Verlust:
$-199.00M
KGV:
-4.5791
EPS:
-3.92
Netto-Cashflow:
$-183.51M
1W Leistung:
+9.92%
1M Leistung:
+28.21%
6M Leistung:
+48.47%
1J Leistung:
+224.59%
1-Tages-Spanne:
$17.37
$18.18
1-Wochen-Bereich:
$16.08
$18.18
52-Wochen-Spanne:
$4.45
$19.18
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
17.95 | 972.79M | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
What does recent volatility data suggest for uniQure N.V.Market Growth Report & Real-Time Volume Analysis - Newser
uniQure reports positive initial data for Fabry disease gene therapy By Investing.com - Investing.com Nigeria
UniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data (NASDAQ:QURE) - Seeking Alpha
Chart based analysis of uniQure N.V. trendsCEO Change & Daily Entry Point Alerts - Newser
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing - GlobeNewswire
uniQure (QURE) Rating Reaffirmed with $70 Price Target by HC Wai - GuruFocus
uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Disease - Benzinga
UniQure Says Early Data for Fabry Disease Gene Therapy Shows Promise - MarketScreener
Long term hold vs stop loss in uniQure N.V.Weekly Trade Report & High Yield Equity Trading Tips - Newser
uniQure reports positive initial data for Fabry disease gene therapy - Investing.com
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease - Ariva
Is uniQure N.V. stock a top performer YTDJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - 더경남뉴스
Is uniQure N.V. exposed to political riskPortfolio Risk Summary & Smart Allocation Stock Reports - 더경남뉴스
uniQure N.V. stock chart pattern explainedJuly 2025 WrapUp & Community Trade Idea Sharing Platform - Newser
Using RSI to spot recovery in uniQure N.V.Index Update & Community Shared Stock Ideas - Newser
Rare Disease Therapy Approvals By FDA Speed Up Via New ProcessNeurogene (NASDAQ:NGNE) - Benzinga
Is uniQure N.V. stock overvalued or fairly pricedJuly 2025 Snapshot & Capital Efficient Trade Techniques - خودرو بانک
What indicators show strength in uniQure N.V.2025 Market Outlook & Free Risk Controlled Daily Trade Plans - Newser
Understanding uniQure N.V.’s price movementWeekly Earnings Recap & Low Drawdown Trading Techniques - Newser
What’s the RSI of uniQure N.V. stockJuly 2025 Movers & Low Risk Growth Stock Ideas - خودرو بانک
Visual analytics tools that track uniQure N.V. performanceQuarterly Portfolio Review & Weekly High Potential Alerts - Newser
Price action breakdown for uniQure N.V.2025 Valuation Update & High Conviction Buy Zone Alerts - Newser
What technical models suggest about uniQure N.V.’s comebackJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - Newser
Is now a turning point for uniQure N.V.Wall Street Watch & Weekly Top Stock Performers List - Newser
Has uniQure N.V. formed a bullish divergenceJuly 2025 Levels & Precise Buy Zone Identification - Newser
Will a bounce in uniQure N.V. offer an exitMarket Activity Summary & Daily Momentum Trading Reports - Newser
Relative strength of uniQure N.V. in sector analysisJuly 2025 Analyst Calls & Daily Technical Stock Forecast Reports - Newser
Ranking uniQure N.V. among high performing stocks via tools2025 Key Lessons & Consistent Growth Equity Picks - Newser
Can uniQure N.V. rally from current levelsJuly 2025 Price Swings & Accurate Buy Signal Alerts - Newser
Using economic indicators to assess uniQure N.V. potential2025 Historical Comparison & Smart Investment Allocation Tips - Newser
Should I hold or sell uniQure N.V. nowJuly 2025 Pullbacks & Real-Time Volume Spike Alerts - خودرو بانک
Can uniQure N.V. outperform in the next rallyJuly 2025 Update & Long-Term Safe Investment Ideas - خودرو بانک
Using data tools to time your uniQure N.V. exitPortfolio Profit Report & Weekly Stock Performance Updates - Newser
Comparing uniQure N.V. in custom built stock radarsAnalyst Downgrade & Long-Term Safe Investment Plans - Newser
Published on: 2025-09-01 20:24:08 - Newser
Technical analysis overview for uniQure N.V. stockPortfolio Return Report & Precise Trade Entry Recommendations - Newser
What’s the outlook for uniQure N.V.’s sectorJuly 2025 Momentum & Verified Stock Trade Ideas - خودرو بانک
Can uniQure N.V. hit a new high this month2025 Bull vs Bear & Growth Focused Entry Point Reports - Newser
Building trade automation scripts for uniQure N.V.2025 Price Action Summary & Long-Term Growth Plans - Newser
Growth Value: Does uniQure N.V. have pricing power2025 Momentum Check & Short-Term Swing Trade Alerts - خودرو بانک
Should you hold or exit uniQure N.V. nowWeekly Investment Summary & Accurate Buy Signal Alerts - Newser
Institutional investors are uniQure N.V.'s (NASDAQ:QURE) biggest bettors and were rewarded after last week's US$53m market cap gain - simplywall.st
Using data filters to optimize entry into uniQure N.V.Analyst Downgrade & Entry and Exit Point Strategies - Newser
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure N V-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Springhorn Jeremy P. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,694 |
| POST LEONARD E | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
29,937 |
| Kaye Jack | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
20,439 |
| Jacques Rachelle Suzanne | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
28,346 |
| Gut Robert | Director |
Jun 20 '25 |
Sale |
14.45 |
3,336 |
48,205 |
56,879 |
| Balachandran Madhavan | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,697 |
| Meek David D. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
34,190 |
| Potts Jeannette | Chief Legal Officer |
Jun 16 '25 |
Sale |
15.14 |
4,670 |
70,704 |
115,073 |
| Kapusta Matthew C | CEO, Managing Director |
Mar 04 '25 |
Sale |
10.29 |
28,341 |
291,629 |
651,454 |
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):